Inclusion Criteria:  Individuals must meet the following inclusion criteria at screening visit:  Male or Female subjects 40-85 years of age. Have chronic corneal edema (for a minimum of 3 months) secondary to endothelial dysfunction. Have corneal thickness >600μm by OCT. Have best corrected distance visual acuity 6/19 (20/63) or worse (equivalent ETDRS= 60 letters) with subjective symptoms of impaired visual function. Subject with posterior pseudophakia and stable IOL. Willing and able to understand and sign informed consent prior to any study related procedure. Willing and able to follow study instructions (e.g., to lay on one's back for 4 hours post op), able to self-administer or have caregiver available to administer eyedrops as required by the protocol for the duration of the study, and able to attend study visits/assessments for the duration of the study.  Exclusion Criteria:  Individuals for participation will be ineligible for the study if any of the following conditions apply:  History of ocular Herpetic keratitis. Scarred cornea resulting in visual impairment with intact endothelium (cell density ≥ 1500). History of posterior vitrectomy. Post PKP Have an irregular posterior cornea (e.g., post trauma). Have a current infection of the cornea. Have band keratopathy and/or limbal stem cell deficiency. Have clinically severe dry eye disease which needs more than 4 drops of lubricant per day. Phthisis bulbi or subject is at risk of developing phthisis. Subject with medically uncontrolled high intra ocular pressure. Aphakia. Anterior chamber IOL or fixated anterior chamber IOL. Pseudophakodonesis. Have large iris defect which could compromise intraoperative air bubble formation Have undergone corneal refractive surgery. History of neurotrophic cornea. History of recurrent corneal erosion or persistent epithelial defect. IridoCorneal Endothelial (ICE) Syndrome or any rare disease/ syndrome creating anatomical or physiological anomalies of the anterior chamber (e.g., corectopia). Recurrent posterior, intermediate or anterior uveitis. Subject receiving regular intravitreal injection Currently participating or have participated in an investigational study, other than this study, within the past 60 days.